GUANGZHOU WONDFO BIOTECH CO.,LTD Guangzhou Wondfo Biotech Co.,Ltd Stock
Equities
300482
CNE100002102
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.9 CNY | +4.55% |
|
+19.50% | -10.84% |
| Sales 2024 * | 3.36B 464M | Sales 2025 * | 3.98B 549M | Capitalization | 12.6B 1.74B |
|---|---|---|---|---|---|
| Net income 2024 * | 650M 89.72M | Net income 2025 * | 760M 105M | EV / Sales 2024 * | 3.74 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.17 x |
| P/E ratio 2024 * |
20.4
x | P/E ratio 2025 * |
16
x | Employees | 3,404 |
| Yield 2024 * |
1.12% | Yield 2025 * |
1.41% | Free-Float | 56.34% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.55% | ||
| 1 week | +19.50% | ||
| Current month | +9.35% | ||
| 1 month | +5.08% | ||
| 3 months | -0.33% | ||
| 6 months | +8.60% | ||
| Current year | -10.84% |
1 week
21.92
26.97
1 month
21.9226.97
Current year
20.5231.00
1 year
20.5232.64
3 years
20.5281.54
5 years
20.5285.38
10 years
4.4785.38
| Managers | Title | Age | Since |
|---|---|---|---|
Zhong Xiong Peng
CEO | Chief Executive Officer | 50 | 09-12-31 |
Ji Hua Wang
FOU | Founder | 61 | 91-12-31 |
Wen Mei Li
FOU | Founder | 61 | 91-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Mei Li
FOU | Founder | 61 | 91-12-31 |
Cui Ling Wu
CHM | Chairman | 62 | 12-04-10 |
Ji Hua Wang
FOU | Founder | 61 | 91-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.21% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 26.9 | +4.55% | 11,734,890 |
| 24-04-23 | 25.73 | +0.94% | 12,785,440 |
| 24-04-22 | 25.49 | +15.34% | 17,016,910 |
| 24-04-19 | 22.1 | -0.45% | 3,592,762 |
| 24-04-18 | 22.2 | -1.38% | 5,494,814 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
GUANGZHOU WONDFO BIOTECH CO., LTD. is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.9
CNY
Average target price
31.73
CNY
Spread / Average Target
+17.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.84% | 1.74B | |
| -0.75% | 12.72B | |
| -11.57% | 7.5B | |
| +2.62% | 5.48B | |
| +0.98% | 4.61B | |
| +5.18% | 4.47B | |
| -50.82% | 3.28B | |
| +11.23% | 2.71B | |
| -18.03% | 2.02B | |
| -2.66% | 1.69B |
- Stock Market
- Equities
- 300482 Stock
